Today, our I3LUNG project was part of that spotlight as Arsela Prelaj from Fondazione IRCCS Istituto Nazionale dei Tumori di Milano presented: “A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC.”
This oral marks an important milestone for our project, and we are grateful to all the colleagues and collaborators whose dedication makes every study, every paper, and every presentation possible.
Great job, Arsela Prelaj and all the team involved.
On day 3 of WCLC2025, Vanja Mišković from Politecnico di Milano presented the study: “An ensemble approach to predict three-class PD-L1 expression from H&E whole-slide images”.
In this video, Vanja explains how the I3LUNG consortium is using routinely collected digital pathology slides from six cancer centers to predict PD-L1 status, a key biomarker for immunotherapy response. By using an ensamble AI model, the team achieves the most accurate predictions and plans to expand and validate the approach with a larger dataset.
Watch the video here!
Today, our PI, Arsela Prelaj, defended our poster “Exploring the potential of multimodal cough analysis as a pre-screening tool for non-small cell lung cancer detection” during the Screening and Early Detection session.
👀 Stay tuned for Day 3 — more updates and insights coming!
What if your voice could help detect lung cancer? 🫁
That’s the question Chiara Giangregorio of Politecnico di Milano asked herself, and the results are in.
Presented on June 1 at American Society of Clinical Oncology (ASCO), our I3LUNG team revealed how acoustic biomarkers combined with AI algorithms could significantly improve NSCLC detection and personalized care.
In this video, Chiara walks us through the poster, the analysis and why this approach could transform early diagnosis in oncology.
This could give lung cancer care a whole new voice.
Watch the video here!
Dr. Sabina Sangaletti from Fondazione IRCCS Istituto Nazionale dei Tumori di Milano presented the poster “Unmasking host immune complexity: single-cell transcriptomic analysis of circulating PBMCs in non-small cell lung cancer treated with immunotherapy-based first line”, sharing with the scientific community a deep and promising insight into immune response in lung cancer.
Keep up the great work, I3LUNG team! 💪🏼
· Decision aids enhance shared decision-making, reduce anxiety, and improve understanding of treatment options.
· Patients value personalized support and clear communication with doctors, but preferences vary (some want detailed info, while others prefer less).
· Tools like brochures or videos can help patients and families, but must avoid adding confusion.
Read more here: https://lnkd.in/dAfqAsfY
Our manuscript “Cost-effectiveness models of non–small cell lung cancer: A systematic literature review” is now available in the Journal of Managed Care & Specialty Pharmacy. This work, developed by our economic partner IHE – The Swedish Institute for Health Economics, marks a significant step in understanding cost-effectiveness models in non-small cell lung cancer.
Thank you to the authors for their effort and dedication:
– Michael Willis, PhD
– Andreas Nilsson, MSc
– Zin Min Thet Lwin, MSc
– Gunnar Brådvik, MSc
– Arsela Prelaj, MD, PhD
Read the full article here: https://lnkd.in/dqUjSp7Z
Michael Willis, from the IHE – The Swedish Institute for Health Economics attended the 2024ISPOR conference in Barcelona this week to present a poster titled “Are 237 Published Cost-Effectiveness Models Necessary for Non-Small-Cell Lung Cancer (NSCLC)? Can Open Source “Model Platforms” Improve Decision-Making and Save Resources?”
Briefly, the poster compares some key characteristics of the identified cost-effectiveness models and tries to answer whether so many unique models are motivated, and explore potential benefits that might accrue if open-source models were made available.
I3LUNG was featured at the ESMO – European Society for Medical Oncology, held from September 13 to 17 in Barcelona.
The poster titled: “Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy” was presented by our PI, Dr. ArselaPrelaj, on September 14th at 11 AM. Additionally, the poster was available for viewing throughout the day, from 9 AM to 5 AM.
Take a look to the I3LUNG poster:
We invite you to watch the video shares more details about our project.
Michael Willis and his team at IHE – The Swedish Institute for Health Economics, have published a groundbreaking article in the Journal of Managed Care & Specialty Pharmacy: “Budget Impact Models for Lung Cancer Interventions: A Systematic Review of the Literature.” This study provides an in-depth perspective on the financial implications of new lung cancer treatments and highlights the need for more accurate and transparent economic evaluations.
In their review of 25 budget impact models (BIMs) for non-small cell lung cancer interventions, the article emphasizes the importance of having rigorous BIMs to guide resource allocation and reimbursement decisions in an ever-evolving landscape. 📊💡
Learn more about this research, which is part of the I3LUNG project, and how it aims to improve patient outcomes through AI-driven decision-making tools.
Link to full paper 👉🏼 https://www.jmcp.org/doi/10.18553/jmcp.2024.30.9.1041